Loading...
NPI 1356320568 · Shreveport, LA · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jeffrey Gosslee is a retina specialist (ophthalmology) physician provider located in Shreveport, Louisiana. This profile covers 19 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jeffrey Gosslee |
| Address | 470 Ashley Ridge Blvd |
| City | Shreveport |
| State | LA |
| ZIP | 71106 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | January 16, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.3M |
| Medicaid | $4.5K |
This provider’s revenue is overwhelmingly Medicare-driven: total Medicare revenue is $2.3M versus total Medicaid revenue of $4.5K, making Medicaid economically immaterial to the practice and effectively single‑payer from a revenue standpoint. The scale of Medicare receipts indicates this clinician’s commercial footprint centers on fee‑for‑service senior care rather than Medicaid populations.
Medicare revenue is highly concentrated: the precomputed top three Medicare codes (J0178, J2777, 92014) account for 82.3% of the provider’s total Medicare revenue, with J0178 contributing $981.7K (43.5%), J2777 contributing $599.4K (26.5%), and 92014 contributing $276.9K (12.3%). This concentration signals heavy reliance on a small set of high‑value services—chiefly intravitreal drug therapy and comprehensive ophthalmic exams.
The procedure mix aligns with a retina‑focused ophthalmology practice: large Medicare revenue from J0178 and J2777 (aflibercept and faricimab injections) combined with substantial billing for retinal imaging (92134) and comprehensive exams (92014) points to an office workflow organized around intravitreal injections plus frequent OCT‑based monitoring of retinal disease. This combination is typical of a clinic that manages chronic retinal conditions requiring repeated anti‑VEGF therapy and imaging follow‑up.
Competitive standing for injectable therapies is moderate rather than dominant nationally: J0178 ranks #860 of 3204 providers nationally (73th percentile; typical, unremarkable volume for this code) and J2777 ranks #461 of 2039 providers nationally (77th percentile; typical, unremarkable volume for this code), indicating the provider bills substantial injection volume but does not appear to be an outlier or market leader for these specific drugs. The sizable dollar contribution of these codes to practice revenue reflects clinical focus more than national market dominance.
The provider is an extreme outlier on exam and imaging volume relative to Medicare peers: 92014 ranks #33 of 35415 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code) and 92134 ranks #187 of 26868 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). These rankings suggest an unusually large panel or exceptionally high follow‑up/monitoring cadence for retinal patients compared with national ophthalmology cohorts.
Several non‑procedure E/M items also show atypically high national standing: 99204 has 329 claims and $34.9K revenue and ranks #942 of 227068 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), which points to a high volume of new patient moderate‑complexity evaluations that likely feed the injection and imaging workflow. The combination of high new‑patient E/M and high exam/imaging volumes is consistent with a practice that receives steady referral traffic and converts evaluations into longitudinal retinal care.
Medicaid billing is minimal and concentrated: the precomputed top three Medicaid codes account for 100.0% of Medicaid revenue, with 92014 representing $3.2K (74.5%) and 92134 representing $1.1K (25.5%) of the $4.5K total. In‑state ranking shows modest Medicaid engagement—92014 ranks #424 of 655 providers in‑state (35th percentile; typical, unremarkable volume) and 92134 ranks #62 of 133 providers in‑state (54th percentile; typical, unremarkable volume)—indicating the provider is not a major Medicaid retinal provider in Louisiana.
The provider has a long tenure in the Medicare system, with NPI enumeration on 2006-01-16 (~20 years ago), which supports interpretation of these billing patterns as established practice behavior rather than a short‑lived spike. Combined with the revenue concentration and high national exam/imaging ranks, the data portray a stable, retina‑specialty practice that derives the bulk of its income from repeat Medicare services tied to intravitreal therapy and monitoring.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,450 | $680 | $981.7K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 22,200 | $30 | $599.4K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 3,420 | $80 | $276.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,590 | $80 | $130.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,680 | $30 | $103K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 330 | $110 | $34.9K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 590 | $60 | $34.2K |
| J9035 | Injection, bevacizumab, 10 mg | 500 | $60 | $27.5K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 20 | $850 | $16.1K |
| 67210 | The provider destroys a lesion of the retina using a laser beam that heats up the tissue. | 40 | $360 | $14.4K |
Showing 1–10 of 19
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
19 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 6 | 50 | 300 | $680 | $371.5K |
| J2777 | 4 | 30 | 6,660 | $30 | $309.4K |
| 67028 | 3 | 70 | 410 | $80 | $44.3K |
| 67042 | 10 | 20 | 20 | $1,110 | $26.6K |
| 92014 | 1 | 470 | 170 | $80 | $23.9K |
| 67108 | 7 | 10 | 20 | $1,100 | $22K |
| 67210 | 6 | 10 | 40 | $380 | $16.5K |
| 92012 | 25 | 350 | 100 | $60 | $11.7K |
| 92235 | 24 | 40 | 70 | $90 | $11.3K |
| J9035 | 4 | 40 | 130 | $50 | $10.8K |
Showing 1–10 of 19
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 460 | $10 | $3.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 550 | $1 | $1.1K |
| 1036F | N/A | 60 | $0 | $0 |
| G8397 | Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy | 60 | $0 | $0 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 90 | $0 | $0 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 10 | $0 | $0 |
| G9974 | Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity | 90 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Louisiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Louisiana median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 424 | 660 | 1,070 | $60 | $129.3K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 62 | 130 | 490 | $10 | $19.4K |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 187 | 250 | 420 | $1 | $50 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 45 | 50 | 190 | $1 | $10 |
| 1036F | N/A | 323 | 380 | 570 | $1 | $1 |
| G8397 | Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy | 4 | 10 | 60 | $0 | $0 |
| G9974 | Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity | 2 | 10 | 190 | $0 | $0 |
Other providers in the same ZIP code as Jeffrey Gosslee, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Pediatria Healthcare, LLC | LA | Medically Fragile Infants and Children Day Care | $0 | $9.8M |
| Laser & Cataract Center Of Shreveport LLC | LA | Ambulatory Surgical Clinic/Center | $2.2M | $231K |
| Steven Heard | LA | Dermatology Physician | $1.4M | $0 |
| Red River Surgery Center LLC | LA | Ambulatory Surgical Clinic/Center | $1.2M | $0 |
| Bryan Vekovius | LA | Specialist | $625.1K | $1.5K |
| Claude Bundrick | LA | Ophthalmology Physician | $373.5K | $0 |
| Pat Bass | LA | Internal Medicine Physician | $355.3K | $0 |
| Ann Guy | LA | Ophthalmology Physician | $333.3K | $0 |
| Anne Bryan | LA | Dermatology Physician | $323.7K | $0 |
| Mobile X-ray Services Of Shreveport Bossier Inc | LA | Portable X-ray and/or Other Portable Diagnostic Imaging Supplier | $198.3K | $105.7K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.